Breaking News

The Ultimate End of Life Planning Checklist

With Pillar, you can get ahead of that by proactively planning. Take things one day at a time so you can be less stressed in the future and focus more on the real things that matter – the person you love.

Philips PET/CT Scanner Vereos, with Ambient Experience Installed at Phoenix Children’s Hospital: To Be Used for Oncological Exams to Help Define the Stage to Which a Cancer Has Developed...

“Working with Philips, we managed to help the children, and also their parents, achieve a sustained sense of calm during the entire PET/CT imaging procedure while enabling faster image acquisition, faster time-to-results, and reduced need for anesthesia,” said Dianna M. E. Bardo MD, Vice-Chair Clinical Development Radiology at Phoenix Children’s Hospital.

Canon Medical Offers New Liver Reporting Tool for Ultrasound

To help easily and accurately determine cut off values, Canon Medical Systems USA, Inc.’s premium AplioTM i-series ultrasound platform is now available with software to display the calculated measurement averages from multiple samples of the liver, customizable based on the “Rule of Four.”

Katherine Singson New CEO of Volpara Solutions

Katherine Singson has been hired as the new CEO of Volpara Solutions.

Katherine Singson role will be to drive continued growth for Volpara’s breast cancer detection and patient tracking software. With 30+ years of experience from start-ups to multinationals including NeXT/Apple®, Pixar® and Microsoft®, Katherine brings both business-to-business as well as direct-to-consumer experience to this crucial new role.

After being mentored by Steve Jobs at all three of his companies, she spent several years abroad including in Sydney, Australia.  A highlight of this time overseas was working at Microsoft ANZ (Australia & New Zealand) where she partnered with Oprah Winfrey’s Ultimate Australian Adventure* to showcase both Windows and Xbox in a deeply humanistic manner.  Katherine is also a recent breast cancer survivor.

Volpara combines artificial intelligence, physics and data to measure breast density for early detection of cancer as well as the clinical management of images. Nearly half of women in the US have dense breast tissue.  Objective breast density analysis can help clinicians and their patients create a plan for ongoing screening based on each woman’s individual risk factors.  Additionally, Volpara’s software provides quality control for mammography centers and patient tracking software.

“As a purpose-driven technology company with the potential to transform the future of breast cancer, we’re excited to have someone of Katherine’s experience unleash our potential,” said Dr. Ralph Highnam, Founder and New Zealand-based Group CEO. “Volpara is already working with luminary customers across the US, including renowned sites in New York, Houston, San Francisco, Austin, Charlotte and Seattle, and of course, we want to reach many more. We look forward to Katherine positively impacting the healthcare industry and seeing how she’ll no doubt tap into the power and passion of women to obliterate advanced-stage breast cancer.”

“In these uncertain times, we aim to create a nimble, responsive and tastefully relentless approach to addressing this destructive disease,” said Katherine. “Since Covid-19, the idea of actively participating in one’s own self-care in partnership with leading-edge healthcare providers is stronger than ever.”

Latest Posts

Segmed Raises $2 Million Seed Round: Financing led by Blumberg Capital

"We aim to aggregate and leverage larger and more representative datasets for use in medical AI to ultimately deliver better healthcare around the world," said Cailin Hardell, co-founder, and CEO, Segmed.

The Ultimate End of Life Planning Checklist

With Pillar, you can get ahead of that by proactively planning. Take things one day at a time so you can be less stressed in the future and focus more on the real things that matter – the person you love.

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.